Tinzaparin for the treatment of foetal growth retardation: An open-labelled randomized clinical trial

Anette Tarp Hansen, Puk Sandager, Mette Ramsing, Olav B Petersen, Jannie D Salvig, Svend Juul, Niels Uldbjerg, Anne-Mette Hvas

4 Citationer (Scopus)

Abstract

OBJECTIVE: Foetal growth retardation (FGR) is a leading cause of perinatal death and long-term harms at survivors. Placental infarction plays a role in FGR, yet, no trials have evaluated whether low molecular weight heparins increase birth weight in ongoing FGR pregnancies.METHODS: An open-labelled randomized trial in Denmark during 2011-2016, including singleton pregnant women with FGR (estimated foetal weight 
OriginalsprogEngelsk
TidsskriftThrombosis Research
Vol/bind170
Sider (fra-til)38-44
ISSN0049-3848
DOI
StatusUdgivet - okt. 2018
Udgivet eksterntJa

Citationsformater